How a drug crosses the blood-brain barrier or the intestinal wall acts as a determining factor in drug development. In the case of central nervous system-related drugs, this is especially true as the drug components which do not possess efficacy in vitro are unable to cross such barriers. These drugs will not be exhibit efficacy in vivo either.
ADME studies play a vital role in checking the determining factor to ensure a drug is effective. Drugs like mibefradil, phenylpropanolamine were pulled off the drug market for toxic interactions. In general, about 40% of drugs fail to pass the toxicity tests and 50% fail to show efficacy all due to the accuracy of ADME assays.
How Relevant Are ADME Studies For Drug Makers?
A 50% failure rate is enough to depict how important ADME studies are beside the assays conducted for pharmacological properties. Without ADME assays the chances of launching an ineffective drug component in the market are very high. This is one of the main reasons such studies are now a part of the early phases of drug development.
FDA Recommendations For ADME Studies
The FDA has a set of recommended guidelines for industry and drug safety measures including drug metabolites, drug-drug interactions, clinical drug interaction, data analysis, good laboratory practices which help evaluate drug safety and efficacy. Toxicokinetics studies and ADME pharmacokinetics studies go hand in hand to check whether the drug can move on to late preclinical stages to fill out New Drug Agreement or maybe a Biologics Licensing Agreement.
How Does It Vary?
With the eccentricities of each drug, it may happen so that different ones have to go through different guidelines and documentation. But for the most part, a combination of GLP and non-GLP labs are used to go through with the toxicokinetics studies. Microsome and hepatocyte models are the most commonly used ones for such studies as they both have CYP450 and UGT.
More Read: 5 Ways To Improve Your Social Health
CYP inhibition and induction assays consider both models. This is a simple example of how ADME studies for different components can still have a similar induction and inhibition procedure depending on certain variables.
The Need For Good Lab Practices: The Backbone Of High-Standard ADME Study
Although it’s clear that there is a mix of non-GLP and GLP in the case of pharmacokinetics studies there is still room for error. Even after following through FDA recommended guidelines, there is a fair share of drug components that fail to make it to the end. This is where GLP plays an important role in ADME studies.
The significance of ADME pharmacokinetics studies in drug development stands on the ground that it acts as a determining factor for drugs to pass on to clinical trials. So the applications, capture data assay, track reagents, calculations of generated data are all backups for these studies to be successful. Only a great research lab can provide the best mechanisms to check all of these factors. This can make or break the standard of ADME pharmacokinetics studies.